NASDAQ$AONC
American Oncology Network In · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Announced fourth quarter and full year 2023 financial results.
American Oncology Network (AON) reported a revenue of $324.2 million for Q4 2023, a 7.9% increase compared to Q4 2022. The increase was primarily driven by a 9.5% growth in patient encounters. However, the company experienced a net loss of $22.4 million, compared to a net income of $1.4 million in the same quarter of the previous year, mainly due to incremental accounts receivable reserves.
- Q4 2023 revenue increased by 7.9% year-over-year to $324.2 million.
- Patient encounters grew by 9.5% compared to the prior year quarter.
- Net loss before non-controlling interest was $22.4 million, driven by incremental accounts receivable reserves.
- Adjusted EBITDA was $5.0 million, a decrease from $8.0 million in the prior year quarter, primarily due to higher drug costs.
Headline financials
Revenue & EPS history
American Oncology Network · Revenue · Quarterly
$324M
Forward guidance
AON didn't provide specific forward guidance in this earnings report.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 1 quarterly earnings reports
-1.0%
Avg return
Earnings day
-7.8%
Avg return
5 days after
-4.0%
Avg return
30 days after
40%
2 / 5 earnings
Positive
+3.3%
Q1 2025
Best reaction
-4.4%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2025 | +3.3% | -0.8% | -11.7% | |
| Q3 2024 | +1.1% | -14.8% | +3.7% | |
| Q2 2024 | -0.9% | — | — | |
| Q1 2024 | — | — | — | |
| Q4 2023 | -4.4% | — | — | |
| Q3 2023 | -4.4% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro